Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03973840 · ClinicalTrials.gov registry record · Phase 1
Assessment of Blood From Men Receiving Oral TU in Various Collection Tubes
A Phase 1 study of Hypogonadism, Male, sponsored by Clarus Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT03973840 is a Phase 1 study of Hypogonadism, Male that has completed, run by Clarus Therapeutics. The registered enrollment target is 13 participants, below the 111-participant average among 12 other Hypogonadism, Male trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03973840, a Phase 1 study of Hypogonadism, Male, has completed, sponsored by Clarus Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
To describe the rate of post-collection TU to testosterone conversion, as manifested by increases in testosterone concentration, in Plain tubes held at room temperature and sodium fluoride (NaF)-ethylenediaminetetraacetic acid (EDTA) tubes held at room temperature or on ice prior to centrifugation
Conditions Studied
Interventions
- DRUG Testosterone Undecanoate
Study Locations (1)
Illinois
- Clarus Therapeutics, Inc - Northbrook
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2018-07-15 |
| Est. Completion | 2018-07-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03973840
The ClinicalTrials.gov registry entry for NCT03973840 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 111-participant average among 12 other Hypogonadism, Male trials with a reported enrollment target (88% lower). The listed sponsor is Clarus Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypogonadism, Male appearing as the primary indexed condition, and to 1 intervention - of which Testosterone Undecanoate is the first listed.
NCT03973840 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT03973840 about?
NCT03973840 is a clinical study titled "Assessment of Blood From Men Receiving Oral TU in Various Collection Tubes". To describe the rate of post-collection TU to testosterone conversion, as manifested by increases in testosterone concentration, in Plain tubes held at room temperature and sodium fluoride (NaF)-ethylenediaminetetraacetic acid (EDTA) tubes held at room temperature or on ice prior to centrifugation
What is the current status of trial NCT03973840?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2018-07-15. Estimated completion is 2018-07-31.
What conditions does trial NCT03973840 study?
This clinical trial studies the following conditions: Hypogonadism, Male.
What interventions are being tested in trial NCT03973840?
The interventions under investigation include: Testosterone Undecanoate (DRUG).
Who is sponsoring clinical trial NCT03973840?
This trial is sponsored by Clarus Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03973840 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypogonadism, Male
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TRT as an Adjunctive ERAS Therapy in ESRD Patients Undergoing Kidney Transplantation
ACTIVE NOT RECRUITING · Phase 1
-
Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism
RECRUITING · Phase 2
-
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
RECRUITING · Phase 2
-
Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone
RECRUITING · Phase 2
-
52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
RECRUITING · Phase 3
-
Testosterone Treatment in Men with Chronic Kidney Disease
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.